infectious-diseases-2016_keynote

2 / 17

Volume 4, Issue 4(Suppl) J Infect Dis Ther 2016
ISSN: 2332-0877, JIDT an open access journal Infectious Diseases 2016
August 24-26, 2016
Page 26
Notes:
conferenceseries.com
August 24-26, 2016 Philadelphia, USA
&
Infectious DiseasesJoint Event on 2nd World Congress on
Pediatric Care & Pediatric Infectious Diseases
International Conference on
Glenn S Tillotson, J Infect Dis Ther 2016, 4:4(Suppl)
The burden of antibiotic resistance
Antimicrobial resistance (AMR) is an escalating problem globally. The consequences of resistance may include increased
morbidity and mortality. However the economic impact of this problem is poorly understood. In addition to enormous
human cost of AMR there have been attempts to estimate the economic costs as well. These would be either direct healthcare
costs such as increased length of hospital stays, loss of productivity or secondary social costs such as foregoing medical
procedures or refraining from travel because of increased risk. In 2013, the CDC estimated that the direct costs of AMR
were US $20 billion with additional productivity losses of US $35 billion. The CDC has also published a list of bacterial
species in which antibiotic resistance has reached significant levels. The impact of antibiotic resistance in five species will be
discussed namely; Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus
pneumoniae. The global implications of antibiotic resistance will be put into perspective.
Biography
Glenn S Tillotson has over 30 years pharmaceutical experience in pre-clinical and clinical research, commercialization, medical affairs, scientific communications
including publication planning strategic drug development, life cycle management and global launch programs. He has been instrumental in the development and
launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin and several other agents. He is a SVP of Medical Affairs where he is preparing for the launch of
solithromycin for community acquired bacterial pneumonia. He has published more than 170 peer-reviewed manuscripts and is on several journal Editorial Advisory
Boards including the Lancet Infectious Disease, eBioMedicine, Expert Reviews in Anti-infective Therapy and F1000.
Glenn S Tillotson
Cempra Pharmaceuticals, USA